|Articles|September 1, 2003

Expensive or Good Deal?

Biologics manufacturers cite complex research and development process,along with FDA scrutiny, as reason for costly - but worthy - drugs

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME